[Hypothalamic factors: recent diagnostic and therapeutic advances]

Area of Science:

• Neuroendocrinology
• Molecular endocrinology
• Neuropeptide research

Background:

• Significant advancements in neuropeptide isolation, characterization, and synthesis.
• Identification of key hypothalamic factors: corticotropin releasing factor (CRF) and growth hormone releasing factor (GRF).

Purpose of the Study:

• To review the progress in neuroendocrinology focusing on hypothalamic factors.
• To explore the synthesis and clinical applications of native neuropeptides and their analogues.

Main Methods:

• Isolation and characterization of hypothalamic factors.
• Synthesis of native neuropeptides and potent analogues (agonists and antagonists).
• Review of clinical applications and therapeutic potential.

Main Results:

• CRF stimulates pituitary secretion of ACTH and pro-opiomelanocortin peptides.
• GRF and somatostatin regulate growth hormone secretion.
• LHRH analogues show promise in treating hormone-related cancers, endometriosis, precocious puberty, and sterility.
• Somatostatin analogues offer therapeutic potential in endocrine and digestive diseases.
• GRF is useful for treating short stature.
• CRF serves as a valuable diagnostic tool.

Conclusions:

• Hypothalamic factors and their analogues have broad clinical applications in endocrine, digestive, and potentially psychiatric diseases, as well as hormone-related cancers.
• While CRF is primarily a diagnostic agent, GRF and other analogues show significant therapeutic promise.